Seqens Seqens

X
[{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla Medpro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cipla Medpro Gets Distribution and Marketing Rights for Seroquel","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Exclusive Promotion Rights to Moksha8, Deepening Strategic Presence in Latin America for CNS Business","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Distribution and Marketing Partnerships in South Korea, Hong Kong, and Thailand for Seroquel\u00ae and Seroquel XR\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"CAP ALTER PHARMA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Signs Two Agreements in Latin America, Global Business System for Seroquel Continues to Grow Rapidly","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"OWP Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OWP Pharmaceuticals Gets IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for Schizophrenia and Bipolar Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Distriphil Enter Exclusive Distribution Partnership in the Philippines with Joint Commitment to Raising Mental Health Awareness","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Grants Cipla Medpro Exclusive Distribution and Marketing Rights for Seroquel\u00ae and Seroquel XR\u00ae in South Africa and Certain Neighbouring Countries","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma Enters Local Seroquel\u00ae Distribution and Marketing Partnership with ICI Pakistan Limited","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the \"We Care About Mental Health\" Initiative","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Gets ANDA Approval for Generic Quetiapine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Quetiapine Hemifumarate

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Luye Pharma grants Auriga exclusive distribution and marketing rights for Seroquel® (quetiapine fumarate, immediate release formulation) and Seroquel XR® (extended release formulation) in Singapore.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: DCH Auriga

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement December 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Luye grants ICI Pakistan exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in Pakistan.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ICI Pakistan Limited

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 26, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Quetiapine fumarate Extended-Release Tablets acts as dopamine type 2 (D2) and serotonin type 2A (5HT2A) antagonism, which is indicated for the treatment of Schizophrenia and Bipolar I disorder.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel XR

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 17, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Luye grants Zuellig exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in Malaysia and Brunei.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Zuellig Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 02, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Luye Pharma grants Distriphil the exclusive distribution and marketing rights for the central nervous system drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in the Philippines.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Distriphil

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Luye grants Distriphil exclusive rights to distribute Seroquel (quetiapine fumarate, immediate release) and Seroquel XR (extended release formulation), atypical anti-psychotic medicines with antidepressant properties, for schizophrenia & bipolar disorder, in the Philippines.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Distribution Solutions

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The potential advantage of this alternative dosage form of Quetiapine Fumarate is that it may be preferred for adult patients who experience swallowing difficulties or for adults and adolescents who have trouble swallowing tablets.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Luye Pharma granted exclusive promotional rights to CAP ALTER PHARMA, INC (Alter-Pharma) for Seroquel products in 9 countries and regions including Costa Rica, Jamaica, Trinidad and Tobago, Barbados, Aruba, Curacao, Bahamas, Bermuda and The Cayman Islands.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Seroquel

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: CAP ALTER PHARMA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Luye Pharma granted Alvogen Korea, Zuellig Pharma and DKSH exclusive distribution and marketing rights to Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in their respective regions of South Korea, Hong Kong and Thailand.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Alvogen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 01, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Moksha8 subsideries, Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda and Moksha8 Farmacéutica, S. de R.L. de C.V have been granted the exclusive promotion rights for the two central nervous system (CNS) drugs: Seroquel® and Seroquel XR® in Brazil and Mexico.

            Lead Product(s): Quetiapine Hemifumarate

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Moksha8

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY